Table 1.
Exerkine | Described source tissues | Mode of intercellular communication | Refs | ||
---|---|---|---|---|---|
Autocrine | Paracrine | Endocrine | |||
Peptides and proteins | |||||
ANGPT1 | Skeletal muscle | ✓ | ✓ | ✓ | 214 |
FGF21* | Skeletal muscle | × | × | ✓ | 190,408 |
GDF15* | Skeletal muscle | ✓ | ✓ | ✓ | 409 |
IL-6* | Skeletal muscle | ✓ | ✓ | ✓ | 410,411 |
IL-7* | Skeletal muscle | ✓ | ✓ | × | 412 |
IL-8* | Skeletal muscle endothelium | ✓ | ✓ | × | 230,413 |
IL-15* | Skeletal muscle | ✓ | ✓ | ✓ | 144,162 |
Musclin | Skeletal muscle | ✓ | ✓ | × | 414 |
Myonectin* | Skeletal muscle | × | × | ✓ | 134,415 |
NTN | Skeletal muscle | ✓ | ✓ | × | 146 |
SPARC* | Skeletal muscle | ✓ | ✓ | × | 130,131 |
VEGF* | Skeletal muscle | ✓ | ✓ | ✓ | 416–420 |
FN1 | Skeletal muscle | × | × | ✓ | 250 |
FST* | Skeletal and cardiac muscle, hepatic | × | × | ✓ | 239,421–423 |
FSTL1* | Adipose, skeletal muscle, cardiac muscle | ✓ | ✓ | ✓ | 31,32,424,425 |
Fractalkine* | Skeletal muscle, endothelium | × | ✓ | ✓ | 145,150,426 |
Irisin* | Skeletal muscle and adipose | ✓ | ✓ | ✓ | 30,180,183,288,427–429 |
ANGPTL4* | Skeletal muscle, adipose, hepatic | ✓ | ✓ | ✓ | 97,243,244 |
Adiponectin* | Adipose | × | ✓ | ✓ | 430–432 |
Apelin* | Adipose | × | ✓ | ✓ | 147,152,433,434 |
TGF-β2* | Adipose | ✓ | ✓ | ✓ | 151 |
RCN2 | Bone marrow macrophages | × | ✓ | × | 124 |
METRLN | Macrophages | ✓ | ✓ | × | 128,186,435 |
IL-10* | Macrophages | ✓ | ✓ | ✓ | 436–439 |
IL-1ra* | Blood mononuclear cells | ✓ | ✓ | ✓ | 438–440 |
Klotho* | Kidney | ✓ | ✓ | ✓ | 132,133,441 |
SDC4* | Hepatic | ✓ | ✓ | ✓ | 135,442 |
BDNF* | Nervous, skeletal muscle | ✓ | ✓ | ✓ | 127,198,443,444 |
NRG1* | Endothelium | × | ✓ | × | 176,445 |
Decorin* | Skeletal muscle | ✓ | ✓ | ✓ | 337,446 |
Cathepsin B* | Skeletal muscle | ✓ | × | ✓ | 204,447 |
GPLD1* | Hepatic | × | × | ✓ | 210 |
PF4 | Platelets | × | × | ✓ | 205–208 |
Adropin* | Hepatic | ✓ | × | ✓ | 248,249,448,449 |
Clusterin* | Unclear | × | × | ✓ | 209,450 |
HSPs* | Various | ✓ | ✓ | ✓ | 451,452 |
Tissue metabolites and lipids | |||||
12,13-diHOME* | Adipose | × | ✓ | × | 56 |
KYNA* | Skeletal muscle | × | ✓ | ✓ | 185,453 |
NO* | Endothelium | ✓ | ✓ | ✓ | 261,454 |
ROS* | Skeletal muscle | ✓ | ✓ | ✓ | 455 |
Catecholamines* | Adrenal gland | × | × | ✓ | 456 |
Lactate* | Skeletal muscle | ✓ | ✓ | ✓ | 41,44,457 |
Succinate* | Skeletal muscle | ✓ | ✓ | ✓ | 52,55 |
L-BAIBA* | Skeletal muscle | ✓ | ✓ | ✓ | 57,58 |
Lac-Phe* | Monocytes, macrophages, epithelial cells | × | × | ✓ | 17 |
Nucleic acids | |||||
microRNAs* | Skeletal muscle | ✓ | ✓ | ✓ | 458–460 |
lncRNAs* | Skeletal muscle | ✓ | × | × | 82,461 |
The selection of exerkines is based on in vivo evidence of signaling molecules that are mobilized in response to acute exercise or exercise training and signal to target tissues. In vitro studies and studies employing external administration of exerkine isolates were not considered. Exerkines that have been investigated in humans are marked with an asterisk
ANGPT1 angiopoietin 1, FGF21 fibroblast growth factor 21, GDF15 growth differentiation factor 1, IL-6 interleukin 6, IL-7 interleukin 7, IL-8 interleukin 8, IL-15 interleukin 15, NTN neurturin, SPARC secreted protein acidic and rich in cysteine, VEGF vascular endothelial growth factor, FST follistatin, FSTL1 follistatin-like 1, ANGPTL4 angiopoietin-like 4, TGF- β2 transforming growth factor β-2, METRLN Meteorin Like, Glial Cell Differentiation Regulator, RCN2 reticulocalbin 2, IL-10 interleukin 10, IL-1ra interleukin 1 receptor antagonist, SDC4 syndecan 4, BDNF brain-derived neurotrophic factor, NRG1 neuregulin 1, HSP heat shock protein, GPLD1 glycosylphosphatidylinositol-specific phospholipase D1, PF4 platelet factor 4, 12,13-diHOME 12,13-dihydroxy-9Z-octadecenoic acid, KYNA kynurenic acid, NO nitric oxide, ROS reactive oxygen species, L-BAIBA β-aminoisobutyric acid, Lac-Phe Lactoylphenylalanine, lncRNA long non-coding RNA